Related Experiment Video
Updated: Jan 8, 2026
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns
Marie-Joelle Jabagi1, Marion Bertrand1, Amélie Gabet1
1French National Agency for Medicines and Health Products Safety and French National Health Insurance (EPI-PHARE), Saint-Denis, France.
Insights
Passive infant immunization with nirsevimab showed lower risks of respiratory syncytial virus (RSV) hospitalization and severe outcomes compared to maternal vaccination with the RSV prefusion F protein (RSVpreF) vaccine. Further studies are needed to reevaluate these strategies.
Area of Science:
- Immunology
- Pediatrics
- Public Health
Background:
- Respiratory syncytial virus (RSV) is a significant cause of infant hospitalizations.
- Two novel preventive strategies, maternal vaccination (RSVpref vaccine) and infant immunization (nirsevimab), have been introduced.
- Comparative effectiveness data between these two RSV prevention methods are currently lacking.
Purpose of the Study:
- To compare the effectiveness of maternal RSVpreF vaccination versus infant nirsevimab immunization.
- To evaluate the prevention of RSV-related hospitalizations in infants.
Main Methods:
- Population-based cohort study utilizing French National Health Data System.
- Infants born between September 1 and December 31, 2024, were included.
- Maternal vaccination (RSVpreF) and infant immunization (nirsevimab) groups were matched 1:1; follow-up until February 28, 2025.
Main Results:
- Nirsevimab was associated with a significantly lower risk of RSV hospitalization (aHR, 0.74; 95% CI, 0.61-0.88) compared to RSVpreF vaccine.
- Passive infant immunization with nirsevimab also reduced severe outcomes, including PICU admission (aHR, 0.58) and need for ventilation (aHR, 0.57).
- Results remained consistent across subgroups and sensitivity analyses.
Conclusions:
- Passive infant immunization with nirsevimab demonstrated superior effectiveness in preventing RSV-related hospitalizations and severe outcomes compared to maternal RSVpreF vaccination.
- These findings represent the initial RSV season utilizing these strategies in France.
- Reevaluation of these immunization strategies in future studies is recommended.
Importance:
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. The comparative effectiveness of 2 recently introduced preventive strategies (infant immunization through placental antibody transfer after maternal vaccination with the RSV prefusion F protein [RSVpreF] vaccine and passive infant immunization with nirsevimab) remains unknown.
Objective:
To compare the associations of maternal vaccination with the RSVpreF vaccine vs passive infant immunization with nirsevimab for the prevention of RSV-related hospitalization.
Design, Setting, And Participants:
This population-based cohort study used data from the French National Health Data System. Maternal vaccination with the RSVpreF vaccine occurred during 32 to 36 weeks' gestation among infants born in mainland France between September 1 and December 31, 2024. Passive infant immunization with nirsevimab occurred prior to hospital discharge. Infants were matched 1:1 by maternity ward discharge date, sex, gestational age, and region. Follow-up ended at the time of RSV hospitalization or death or on February 28, 2025.
Exposures:
Maternal immunization with the RSVpreF vaccine and passive infant immunization with nirsevimab.
Main Outcomes And Measures:
The primary outcome was hospitalization for RSV-associated lower respiratory tract infection. The secondary outcomes included admission to the pediatric intensive care unit (PICU), admission to high-dependency unit, ventilator support, and oxygen therapy. The hazard ratios (HRs) were estimated using conditional Cox proportional hazards models with inverse probability of treatment weighting.
Results:
A total of 42 560 infants (mean age, 3.7 [SD, 1.4] days; 51.7% male) were included in the study (21 280 per group) with a median follow-up of 84 days (IQR, 70-99 days). Of the 481 hospitalizations for RSV-associated lower respiratory tract infection, 212 (44.1%) occurred in the nirsevimab group vs 269 (55.9%) in the RSVpreF vaccine group (between-group difference, -11.8% [95% CI, -18.1% to -5.5%]). Compared with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with a lower risk of hospitalization for RSV-associated lower respiratory tract infection (adjusted HR, 0.74 [95% CI, 0.61 to 0.88]). Compared with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with a lower risk of severe outcomes, including PICU admission (adjusted HR, 0.58 [95% CI, 0.42 to 0.80]), requiring ventilator support (adjusted HR, 0.57 [95% CI, 0.40 to 0.81]), or requiring oxygen therapy (adjusted HR, 0.56 [95% CI, 0.38 to 0.81]). The results were consistent across subgroups and in the sensitivity analyses.
Conclusions And Relevance:
Compared with maternal vaccination with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes. These findings reflect the first RSV season with use of these immunization strategies in mainland France; their use should be reevaluated in future studies.
More Related Videos
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:51Vaccinations